bucillamine / Revive Therap, Supriya Lifesci - LARVOL DELTA

CLINICAL SIGNIFICANCE OF GLOMERULAR NELL1 AND PLA2R STAINING IN MEMBRANOUS NEPHROPATHY ASSOCIATED WITH RHEUMATOID ARTHRITIS (ISN-WCN 2026) - "In patients with rheumatoid arthritis (RA), Neural epidermal growth factor-like 1 (NELL1)-positive MN induced by the anti-rheumatic drug bucillamine has been reported...These findings suggest that antigenic diversity in RA-associated MN affects clinical outcomes, and in patients with multiple target antigens, the course may reflect combined features of both NELL1 and PLA2R. Understanding this antigenic heterogeneity is essential for accurate classification and individualized management of MN in RA."

Clinical • Glomerulonephritis • Immunology • Inflammatory Arthritis • Renal Disease • Rheumatoid Arthritis • Rheumatology • EGF • NELL1

Successful Reintroduction of Golimumab in a Patient With Rheumatoid Arthritis and Prolonged Epstein-Barr Virus Reactivation With Persistent Anti-Viral Capsid Antigen IgM Antibodies: A Case Report. (PubMed, Cureus) - "We report the case of a 63-year-old male patient with rheumatoid arthritis (RA) who experienced Epstein-Barr virus (EBV) reactivation during treatment with methotrexate (MTX) and anti-tumor necrosis factor-alpha (TNF-α) antibody, golimumab (GLM)...Two months later, RA relapsed and was managed with prednisolone, bucillamine, and salazosulfapyridine, but disease activity persisted. GLM was reintroduced one year after EBV reactivation, resulting in sustained remission without EBV-related complications, despite continued positivity for viral markers. This case highlights the potential feasibility of resuming anti-TNF-α antibody therapy in patients with RA exhibiting prolonged EBV reactivation and sustained IgM seropositivity under close monitoring."

Journal • Epstein-Barr Virus Infections • Immunology • Inflammatory Arthritis • Oncology • Rheumatoid Arthritis • Rheumatology

A case of bucillamine-induced membranous nephropathy presenting with acute kidney injury and requiring hemodialysis. (PubMed, CEN Case Rep) - "We present kidney biopsy findings in a 65-year-old male patient with rheumatoid arthritis who developed severe proteinuria 10 months after bucillamine administration and required hemodialysis 14 days later. The following mechanism is speculated as the cause of AKI. Although the arteriosclerotic lesions were mild in the kidney biopsy specimen, the severe hypoalbuminemia caused by severe proteinuria, combined with the drop in blood pressure due to losartan administration, led to an ischemic state, which is thought to have led to the onset of AKI."

Journal • Acute Kidney Injury • Atherosclerosis • Glomerulonephritis • Hypotension • Immunology • Inflammatory Arthritis • Nephrology • Pain • Renal Disease • Rheumatoid Arthritis • Rheumatology • EGF

Rheumatoid Factor Levels Are Associated With Arthritis Exacerbation After Bucillamine Discontinuation. (PubMed, Int J Rheum Dis) - "Following bucillamine discontinuation, arthritis exacerbations occurred more frequently in patients with rheumatoid factor levels of 28 U/mL or higher, alongside an increase in these levels. Rheumatoid factor levels may serve as a useful biomarker for identifying patients who would benefit from continued bucillamine therapy."

Biomarker • Journal • Retrospective data • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

High MDR1 expression in rheumatoid arthritis is associated with increased MMP-3 levels and use of bDMARDs: potential independence of JAK inhibitors from MDR1. (PubMed, Rheumatology (Oxford)) - "High MDR1 expression correlates with elevated MMP-3 levels and more frequent bDMARDs use. JAK inhibitors remain effective regardless of MDR1 status, potentially bypassing MDR1-mediated cellular drug resistance in RA."

Journal • Immunology • Inflammatory Arthritis • Orthopedics • Pain • Rheumatoid Arthritis • Rheumatology • ABCB1 • ICAM1 • MMP1 • MMP3

Alpha-Lipoic Acid as a Reversible Trigger for NELL1-Associated Membranous Nephropathy: A Case Report (KIDNEY WEEK 2025) - "Although first linked to malignancy, NELL1 MN is increasingly associated with thiol-containing compounds such as bucillamine, tiopronin, and alpha lipoic acid (ALA)...Losartan, atorvastatin, and dapagliflozin were started...Clinicians should inquire about non-prescription supplements. Discontinuing ALA may allow remission without immunosuppressive therapy."

Case report • Clinical • Diabetes • Diabetic Neuropathy • Dyslipidemia • Fibrosis • Genetic Disorders • Glomerulonephritis • Human Immunodeficiency Virus • Immunology • Infectious Disease • Metabolic Disorders • Nephrology • Obesity • Renal Disease • Type 2 Diabetes Mellitus • EGF • NELL1

Drug Repurposing Patent Applications January-March 2025. (PubMed, Assay Drug Dev Technol) - "Few researchers would have expected that SSRI antidepressants such as sertraline and indatraline could exhibit pronounced anticancer effects. Equally unexpected is the disclosure that sitagliptin, the first antidiabetic agent from the DPP-4 inhibitor class, may be used for the treatment of glioblastoma...In addition, the compound bucillamine-relatively obscure in Western medicine but long used for the treatment of rheumatoid arthritis in East Asia-has been proposed for potential benefit in organophosphate poisoning. These highlights exemplify the breadth of innovation currently shaping the drug repurposing landscape. The reviewed patent applications originate from a diverse range of jurisdictions, including France, Spain, Greece, Slovenia, South Korea, China, Japan, Canada, and the United States, illustrating the global nature of ongoing research efforts in this field."

Journal • Brain Cancer • CNS Disorders • Glioblastoma • Hematological Malignancies • Immunology • Infectious Disease • Inflammatory Arthritis • Malaria • Myelodysplastic Syndrome • Oncology • Psychiatry • Rheumatoid Arthritis • Rheumatology • Solid Tumor

Drug-Induced Pemphigus Foliaceus Potentially Triggered by Piperacillin-Tazobactam, Linezolid, and Additional Factors: A Report of a Rare Case. (PubMed, Cureus) - "Drug-induced pemphigus (DIP) is a rare autoimmune blistering disorder most commonly associated with thiol-containing drugs such as penicillamine, captopril, and bucillamine. However, additional medications are increasingly recognized in the nonthiol nonphenol group. While the exact mechanism of DIP remains unclear, potential pathways include antigen modification, immune dysregulation, or oxidative stress. This case highlights the need for heightened awareness of atypical triggers, comprehensive diagnostics, and timely intervention to optimize patient outcomes."

Journal • Dermatology • Immunology • Pemphigus Vulgaris

Bucillamine-induced Yellow Nail Syndrome with Chylothorax: A Case Report. (PubMed, Intern Med) - "The chylothorax persisted despite the discontinuation of bucillamine. The present case illustrates that bucillamine can cause irreversible lymphatic impairment and chylothorax."

Journal • Inflammation • Respiratory Diseases

Bucillamine-induced membranous nephropathy versus primary membranous nephropathy: comparing pathological features and kidney prognosis. (PubMed, Sci Rep) - "Clinically, the majority of patients in the BCL-MN group experienced proteinuria resolution after 1 year of drug discontinuation alone, and there was no progression of renal function decline. BCL-MN differs from p-MN both histologically and clinically, which may be related to the mechanism induced by BCL."

Journal • Glomerulonephritis • Immunology • Inflammatory Arthritis • Renal Disease • Rheumatoid Arthritis • Rheumatology

NELL1-Positive Membranous Nephropathy in Renal Allografts: A Series of Six Patients. (PubMed, Am J Transplant) - "None of the patients in this series had known triggers of MN, such as malignancy or associated medications (including lipoic acid, bucillamine, tiotropin, or indigenous medicines). This suggests that NELL1, though not a podocyte antigen, may present as an idiopathic disease or transplantation may serve as an exposure for the development of NELL1+ MN."

Journal • Glomerulonephritis • Nephrology • Oncology • Renal Disease • Transplantation • EGF • NELL1

Pharmaceutical Interventions for the Management of Hemorrhagic Shock in Hepatic Surgery: An Experimental Swine Model Outcome. (PubMed, Cureus) - "This study examines the effectiveness of combining standard fluid therapy with antioxidants (bucillamine and valproic acid) in mitigating oxidative stress and reducing hepatocyte damage in the context of hemorrhagic shock.  Method Thirty male swine were randomly divided into four groups as follows: Group A (n=6/control group), Group B (n=8), Group C (n=8), and Group D (n=8)...Conclusion These findings suggest that incorporating antioxidant therapy into resuscitation protocols may offer substantial benefits in mitigating hepatic damage associated with hemorrhagic shock. This approach could potentially improve outcomes in clinical settings where oxidative stress plays a critical role in injury progression by better understanding the pathophysiology of this complex and dynamic process."

Journal • Surgery • Cardiovascular • Hematological Disorders • Hepatology • Reperfusion Injury

Clinicopathological characteristics of neural epidermal growth factor-like 1 protein-associated membranous glomerulonephritis. (PubMed, Virchows Arch) - "The characteristic histological feature of segmental distribution in NELL1-positive MGN may be related to bucillamine use and the early phase of the disease. Further investigations with larger numbers of patients may offer further insight into the prognosis of patients with NELL1-positive MGN."

Journal • CNS Disorders • Glomerulonephritis • Lupus Nephritis • Nephrology • Psychiatry • EGF • NELL1

NELL1 membranous nephropathy: clinical associations provide mechanistic clues. (PubMed, Front Nephrol) - "It has been associated with a variety of exposures and secondary conditions, specifically use of thiol-containing medications - including lipoic acid, bucillamine, and tiopronin - as well as traditional indigenous medications (TIM) particularly those with high mercury content, and non-steroid anti-inflammatory drugs (NSAIDs)...Genome-wide association study of NELL1, role of NELL1 in other physiologic and pathologic processes, and connection between NELL1 MN and malignancy with relevance of NELL1 tumor staining are examined. Finally, relationships and potential disease mechanisms of thiol- and mercury- associated NELL1 MN are discussed."

Journal • Review • Glomerulonephritis • Graft versus Host Disease • Immunology • Infectious Disease • Nephrology • Oncology • Psychiatry • Renal Disease • NELL1

Lymphoproliferative disorder progressing after partial remission following immunosuppressive drugs withdrawal in a patient with rheumatoid arthritis. (PubMed, Mod Rheumatol Case Rep) - "Here, we report a 73-year-old woman was diagnosed with RA at 60 years of age and treated with methotrexate, bucillamine, prednisolone, and infliximab...After pulse steroid therapy, the patient received rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone therapy, which resulted in a complete response. In conclusion, when LPDs develop in patients with RA during ISD treatment, LPDs can progress and complicate HPS after partial remission following ISDs withdrawal. Therefore, we should carefully follow up RA patients with LPDs, aim to achieve an early diagnosis of LPD, and promptly initiate chemotherapy."

Journal • Diffuse Large B Cell Lymphoma • Epstein-Barr Virus Infections • Hematological Disorders • Hematological Malignancies • Immunology • Inflammatory Arthritis • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Rheumatoid Arthritis • Rheumatology

Oral intake of bucillamine, carvedilol, metformin, or phenformin does not protect against UVR-induced squamous cell carcinomas in hairless mice. (PubMed, Photochem Photobiol Sci) - "Metformin treatment significantly reduced UVR-induced erythema (P = 0.012), bucillamine and phenformin increased dorsal pigmentation (P = 0.0013, and P = 0.0005), but no other photoprotective effect was observed across the repurposed groups. This study demonstrates that oral supplementation with bucillamine, carvedilol, metformin, or phenformin does not affect UVR-induced carcinogenesis in hairless mice."

Journal • Preclinical • Dermatology • Genetic Disorders • Non-melanoma Skin Cancer • Oncology • Skin Cancer • Squamous Cell Carcinoma

Dual stimuli-responsive and sustained drug delivery NanoSensoGel formulation for prevention of cisplatin-induced ototoxicity. (PubMed, J Control Release) - "Cisplatin (CisPt)-induced ototoxicity (CIO) is delineated as a consequence of CisPt-induced intracellular generation of reactive oxygens species (ROS) which can be circumvented by Bucillamine (BUC; an antioxidant drug with sulfhydryl groups) and Diltiazem (DLT, L-type calcium channel blocker). The NanoSensoGel showed sustained release of BUC and DLT following Fickian release diffusion kinetics determined using the Korsmeyer-Peppas model. Overall, a novel NanoSensoGel formulation has demonstrated its great potential in delivering therapeutics in the inner ear for prophylactic treatment of CIO, and associated hearing loss."

Journal • Otorhinolaryngology • CASP3 • CASP7

Response to Letter to the Editor entitled "Adding Cases to the Study of Bucillamine-Associated Neural Epidermal Growth Factor Like1-Positive Membranous Nephropathy". (PubMed, Kidney Int Rep) - No abstract available

Journal • Glomerulonephritis • Renal Disease

Adding Cases to the Study of Bucillamine-Associated Neural Epidermal Growth Factor-Like1-Positive Membranous Nephropathy. (PubMed, Kidney Int Rep) - No abstract available

Journal • Glomerulonephritis • Renal Disease

Chiral discrimination of cyclodecapeptide to anti-COVID-19 clinical candidates: a theoretical study. (PubMed, Struct Chem) - "In this work, we employed cyclic decapeptide as the host molecule and the M06-2X theoretical computational method for chiral recognition of four clinical candidate guests and their isomers, including bucillamine, molnupiravir, azvudine, and VV116, which are relevant for the treatment of COVID-19. These findings might provide a theoretical reference for the identification and separation of chiral compounds in host-guest interaction. The online version contains supplementary material available at 10.1007/s11224-023-02149-5."

Journal • Infectious Disease • Novel Coronavirus Disease

Bucillamine in Treatment of Patients With COVID-19 (clinicaltrials.gov) - P3 | N=695 | Terminated | Sponsor: Revive Therapeutics, Ltd. | N=1000 ➔ 695 | Trial completion date: Dec 2022 ➔ Jun 2023 | Enrolling by invitation ➔ Terminated | Trial primary completion date: Dec 2022 ➔ Jun 2023; Met definition of futility according to DSMB

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Infectious Disease • Novel Coronavirus Disease

Immunosuppressive therapy and humoral response to third mRNA COVID-19 vaccination with a six-month interval in rheumatic disease patients. (PubMed, Rheumatology (Oxford)) - "Repeated vaccinations in many immunosuppressed patients produced antibody responses similar to those observed in HCs. In contrast, annual vaccination in patients receiving TNF inhibitors, abatacept, mycophenolate mofetil and rituximab may require caution."

Journal • Immunology • Infectious Disease • Inflammatory Arthritis • Novel Coronavirus Disease • Oncology • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • IL6

Neural Epidermal Growth Factor-Like 1-Positive Membranous Nephropathy With Rheumatoid Arthritis. (PubMed, Kidney Int Rep) - No abstract available

Journal • Glomerulonephritis • Immunology • Inflammatory Arthritis • Nephrology • Renal Disease • Rheumatoid Arthritis • Rheumatology

"#bucillamine has great potential to treat covid! https://t.co/7z2IIUswuH" (@kindmafia11111)

Novel Coronavirus Disease

Investigation of Bucillamine as anti-COVID-19 drug: DFT study, molecular docking, molecular dynamic simulation and ADMET analysis. (PubMed, J Biomol Struct Dyn) - "Finally, an in silico study was performed to predict drug-likeness and absorption, distribution, metabolism, excretion and toxicity profiles (ADMET) of BUC. These results propose that BUC can be a potential drug candidate against the COVID-19 disease progression.Communicated by Ramaswamy H. Sarma."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases